腹主动脉瘤患者多部位血管扩张或动脉瘤与基质金属蛋白酶基因变异的关系
研究纳入169例腹主动脉瘤患者,检测MMP1、3、9、12基因多态性与胸主动脉及腘动脉扩张或动脉瘤的关联。MMP9 rs2234681微卫星≥22 CA重复等位基因携带者胸主动脉扩张或动脉瘤风险增加5.9倍,MMP12 rs652438 C等位基因携带者腘动脉扩张或动脉瘤风险增加2.8倍。
要点
- MMP9 rs2234681≥22 CA重复等位基因与胸主动脉扩张或动脉瘤独立相关。
- MMP12 rs652438 C等位基因与腘动脉扩张或动脉瘤风险增加相关。
- 联合高胆固醇血症和抗血小板使用可提高胸主动脉瘤阴性预测值。
核心结论
- 腹主动脉瘤患者中,MMP9 rs2234681≥22 CA重复纯合携带者胸主动脉扩张或动脉瘤风险显著增加。
- MMP12 rs652438 C等位基因携带者腘动脉扩张或动脉瘤风险显著增加。
研究设计与样本
- 连续纳入169例腹主动脉瘤患者,检测MMP1、MMP3、MMP9和MMP12功能基因多态性。
- 评估胸主动脉扩张或动脉瘤(最大直径>35 mm)及腘动脉扩张或动脉瘤(直径>10 mm)的关联。
主要发现
- 胸主动脉扩张或动脉瘤检出34例,患病率20.1%。
- MMP9 rs2234681微卫星是胸主动脉扩张或动脉瘤唯一遗传决定因素(P=.003)。
- ≥22 CA重复等位基因携带者胸主动脉扩张或动脉瘤风险增加5.9倍(95%CI 1.9-18.6,P<.0001)。
- 腘动脉扩张或动脉瘤发生于55例患者,患病率33.1%。
- MMP12 rs652438 C等位基因携带者腘动脉直径增加18%(P=.006),腘动脉扩张或动脉瘤风险增加2.8倍(95%CI 1.3-6,P=.008)。
关键数值与推荐
- 胸主动脉扩张或动脉瘤定义为最大直径>35 mm。
- 腘动脉扩张或动脉瘤定义为直径>10 mm。
- 联合MMP9 rs2234681、高胆固醇血症和抗血小板使用对胸主动脉瘤检测的阴性预测值为98%,阳性预测值为30%。
临床怎么用
- 对腹主动脉瘤患者可考虑检测MMP9 rs2234681和MMP12 rs652438以评估胸主动脉及腘动脉扩张风险。
- MMP9 rs2234681≥22 CA重复携带者应关注胸主动脉扩张或动脉瘤筛查。
- MMP12 rs652438 C等位基因携带者应关注腘动脉扩张或动脉瘤评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess whether functional genetic polymorphisms of matrix metalloproteinases (MMPs) 1, 3, 9, and 12 are associated with arterial enlargements or aneurysms of the thoracic aorta or popliteal arteries in patients with abdominal aortic aneurysm (AAA). METHODS: The associations between MMP1 (-1607 G in/del, rs1799750), MMP3 (-1171 A in/del rs35068180), MMP9 (13-26 CA repeats around -90, rs2234681, rs917576, rs917577), and MMP12 (G/T missense variation, rs652438) polymorphisms and enlargements or aneurysms of the thoracic aorta and popliteal arteries were tested in 169 consecutive AAA patients. RESULTS: Thoracic aorta enlargement or aneurysm (TE/A; maximum diameter, >35 mm) was detected in 34 patients (20.1% prevalence). MMP9 rs2234681 microsatellite was the only genetic determinant of TE/A in AAA patients (P = .003), followed by hypercholesterolemia and antiplatelet use. Carriers of both alleles with ≥22 CA repeats had a 5.9 (95% confidence interval, 1.9-18.6; P < .0001) increased odds of TE/A, and a score considering all three variables showed 98% negative predictive value and 30% positive predictive value for thoracic aortic aneurysm detection. Eighty-two popliteal artery enlargements or aneurysms (diameter >10 mm) occurred in 55 patients (33.1% prevalence). Carriers of MMP12 rs652438 C allele showed an 18% (P = .006) increased diameter in popliteal arteries and a 2.8 (95% confidence interval, 1.3-6; P = .008) increased odds of popliteal artery enlargement or aneurysm compared with TT genotype. CONCLUSIONS: Among patients with AAA, carriers of homozygous ≥22 CA repeats in MMP9 rs12234681 and of C allele in MMP12 rs652438 have a substantial risk of carrying thoracic and popliteal enlargements, respectively.
引用
- Fiotti N, Calvagna C, Sgorlon G, et al. Multiple sites of vascular dilation or aneurysmal disease and matrix metalloproteinase genetic variants in patients with abdominal aortic aneurysm. J Vasc Surg. 2017. PMID: 29291905. doi:10.1016/j.jvs.2017.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。